Market Analysis and Insight: Europe Anticoagulation Therapy Market
Europe Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) – Industry Trends and Forecast to 2026
Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open. Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi. There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).
Europe anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.
Get a Sample Copy of report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=eur...
Segmentation: Europe Anticoagulation Therapy Market
Europe anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.
• On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others
• On the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and others
• On the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others
• On the basis of route of administration, the market is segmented into oral and injectable
• On the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others
• On the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement
• On the basis of type, the market is segmented into generics and branded
• On the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others
• On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy
Competitive Analysis: Europe Anticoagulation Therapy Market
Some of the major players operating in the Europe anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.
Get Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=europe-anticoagu...
Recent Developments
• In September 2018, Sanofi announced Health got Canada approval for Lovenox’s (enoxaparin sodium) new indication toprevent thrombus formation in the extra-corporeal circulation during haemodialysis in patients who are having end stage kidney disease (ESKD). This will attract the potential consumers helping in the growth of the company.
• In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg. It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD). This approval will help the company to develop anticoagulant business in European countries.
• In June 2015, Daiichi Sankyo Company, Limited received the EU approval for LIXIANA (edoxaban). It is a branded version of edoxaban. It is developed to reduce chances of stroke and systemic embolism (SE) in patients having non-valvular atrial fibrillation (NVAF). This product approval will help to expand Daiichi’s product portfolio in Europe as company can market it in to all European States.
Research Methodology: Europe Anticoagulation Therapy Market
Primary Rependants:
Key Opinion Leaders (KOL’s): Manufacturers, Researchers, Distributors, Bakers and Food Industrialists.
Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and National Sales Managers.
For More Information or Query or Looking for Customization, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbm...
Browse more related report to know about market analysis
• Asia-Pacific Anti-Nuclear Antibody Test Market
• Asia-Pacific Rx Dermatology Topical Drug Delivery Market
• Europe Anticoagulation Therapy Market
• Europe Dry Eye Syndrome Treatment Market
• Ameloblastic Carcinoma Market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact: Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]